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background. The strength of the association between intensive care unit (ICU)–acquired nosocomial infections (NIs) and mortality
might differ according to the methodological approach taken.
objective. To assess the association between ICU-acquired NIs and mortality using the concept of population-attributable fraction
(PAF) for patient deaths caused by ICU-acquired NIs in a large cohort of critically ill patients.
setting. Eleven ICUs of a French university hospital.
design. We analyzed surveillance data on ICU-acquired NIs collected prospectively during the period from 1995 through 2003. The
primary outcome was mortality from ICU-acquired NI stratified by site of infection. A matched-pair, case-control study was performed.
Each patient who died before ICU discharge was defined as a case patient, and each patient who survived to ICU discharge was defined
as a control patient. The PAF was calculated after adjustment for confounders by use of conditional logistic regression analysis.
results. Among 8,068 ICU patients, a total of 1,725 deceased patients were successfully matched with 1,725 control patients. The
adjusted PAF due to ICU-acquired NI for patients who died before ICU discharge was 14.6% (95% confidence interval [CI], 14.4%–14.8%).
Stratified by the type of infection, the PAF was 6.1% (95% CI, 5.7%–6.5%) for pulmonary infection, 3.2% (95% CI, 2.8%–3.5%) for
central venous catheter infection, 1.7% (95% CI, 0.9%–2.5%) for bloodstream infection, and 0.0% (95% CI, 0.4% to 0.4%) for urinary
tract infection.
conclusions. ICU-acquired NI had an important effect on mortality. However, the statistical association between ICU-acquired NI
and mortality tended to be less pronounced in findings based on the PAF than in study findings based on estimates of relative risk.
Therefore, the choice of methods does matter when the burden of NI needs to be assessed.
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Intensive care unit (ICU)–acquired nosocomial infections
(NIs) are thought to increase patient mortality.1-3 However,
the magnitude of this effect remains controversial and de-
pends on study design, type of infection, and target popu-
lation.4-12 Previous investigations have reported mortality es-
timates related to ICU-acquired NI of 4%–50%.1-6,9,10 The
corresponding relative risks of death due to ICU-acquired NI
were 1.4–4.0, and the corresponding odds ratios were 1.7–
3.2.3,4,8-12
The population-attributable fraction (PAF) of death is a
well-known public health concept, defined as “the fraction
of patients that would not have died if exposure had not
occurred.”13 Various epidemiologic methods can be used to
evaluate the PAF, including expert assessment of case series.
In contrast to the rich literature available in the field of
chronic disease epidemiology, controlled studies aiming to
determine the proportion of hospital deaths attributable to
NI are both rare and insufficient for the calculation of sta-
ble estimates.14,15 Furthermore, several methodological issues
have to be considered, since the causal relationship between
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table 1. Characteristics of Intensive Care Unit Patients Excluded from and Included in the Study
Characteristic
Excluded
patients
(n p 4,178
[34.1%])
Included patients
Unexposed
patients
(n p 6,391
[52.2%]) P a
Exposed
patients
(n p 1,677
[13.7%]) P a
All included
patients
(n p 8,068
[65.9%]) P a
Male sex 2,453 (58.7) 4,193 (65.6) .001 1,071 (63.9) .001 5,264 (65.2) .001
Age, years 57.4  19.3 58.5  17.5 .005 58.7  17.6 .025 58.5  17.5 .002
Length of stay, days 5.2  4.5 7.8  6.0 .001 15.5  7.6 .001 9.4  7.1 .001
Died before discharge 363 (8.7) 1,279 (20.0) .001 556 (33.2) .001 1,835 (22.7) .001
Immunocompromised 448 (10.7) 1,112 (17.4) .001 245 (14.6) .001 1,357 (16.8) .001
SAPS II 30.6  15.2 39.3  18.1 .001 43.1  17.0 .001 40.1  17.9 .001
note. Values are expressed as no. (%) for qualitative variables and as mean  SD for quantitative variables. SAPS II, Simplified
Acute Physiology Score; SD, standard deviation.
a The x2 test was used to compare categorical variables, and the Student t test was used to compare continuous variables.
exposure (to a pathogen that causes NI) and death can be
jeopardized by multiple confounders and biases, such as se-
verity of the underlying illness and the infection type.1,2,10 In
addition, small sample size can be associated with statistical
power inadequate to generate meaningful PAF estimates.16
The objective of this case-control study was to provide
accurate estimates of the adjusted PAF of ICU-acquired NI
in a large cohort of critically ill patients.
methods
Patients and Setting
Our study was based on data collected prospectively by a
nosocomial infection surveillance network17,18 during the pe-
riod from January 1, 1995, through December 31, 2003, from
11 adult ICUs at the University Hospital of Lyon, France.
Design
A case-control study with individual pair matching was un-
dertaken according to the approach proposed by Bruzzi et
al.19 Case patients were patients who died before ICU dis-
charge, whereas control patients were patients who survived
to discharge. For each case patient, 1 control patient from
the same ICU was selected and matched according to the
following criteria: sex, age (stratified into 7 age groups), and
year of admission. If multiple control patients were available,
the one with the date of admission closest to that of the case
patient was retained. The following variables were collected
and analyzed as potential confounders: Simplified Acute
Physiology Score at ICU admission, immunodepression, and
type of condition at admission (medical, surgical, or
trauma).20,21 All variables were collected according to the cri-
teria of a standardized and validated protocol, established by
an ICU surveillance network in France.17,18
Definitions of ICU-Acquired NI
We defined various risk levels of patient death before dis-
charge from the ICU according to exposures to ICU-acquired
NI. Exposure was defined as the presence of at least one ICU-
acquired NI in a given patient, ascertained according to a
standardized protocol and established guidelines.17,18,22,23 ICU-
acquired NI was defined as infection that occurred at least
48 hours after admission to the ICU, determined on the basis
of clinical and microbiological criteria.17,18,22,23 The 4 types of
ICU-acquired NI considered for analysis were pulmonary in-
fections, central venous catheter (CVC) infections, urinary
tract infections (UTIs), and bloodstream infections (BSIs).
For each patient, only the first infection in any of these 4
sites was analyzed. We calculated the incidence of ICU-ac-
quired NI as the number of cases of ICU-acquired NI per
100 patients per period (period was the duration of the stay
in the hospital).
We stratified analysis by type of infection and number of
infected sites. To further explore the complex association be-
tween ICU-acquired NI and death in the ICU, we fitted 5
different models, stratified by type of infection and number
of infected sites (see Appendix, Table A). The first model
included any type of infection during the ICU stay that oc-
curred in any of the 4 body sites. For this model, only the
first ICU-acquired NI for each patient was taken into account.
The other 4 subgroup models dealt with each type of ICU-
acquired NI separately. For each of these models, patients
with ICU-acquired NI at only 1 specific, primary site were
compared with a patient group without ICU-acquired NI (no
infection), with a group who had at least 1 ICU-acquired NI
at the primary site with coinfection at 1 or more of the 3
other sites, and finally with a group of patients who had ICU-
acquired NI at 1 or more of the 3 other sites but no infection
at the primary site.
Statistical Analysis
We used the McNemar test to compare proportions and the
paired Student t test to compare means. Calculation of the
crude PAF of deaths related to ICU-acquired NI was based
on the following equation using the relative odds of death
(ROD):24
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table 2. Entry Characteristics of Case Patients Who Died before
Dischange and Matched Control Patients Who Survived to Dis-
charge in 11 Intensive Care Units (ICUs) at the University Hospital
of Lyon, 1995–2003
Characteristic
Case
patients
(n p 1,725)
Control
patients
(n p 1,725) P a
Length of ICU stay, days 9.6  7.1 10.1  7.3 .031
SAPS II 52.4  18.5 38.5  16.2 !.001
Immunocompromised 314 (18.2) 258 (15.0) !.001
Admission condition !.001
Medical 435 (25.2) 565 (32.8)
Surgical 1,079 (62.6) 892 (51.7)
Trauma 211 (12.2) 268 (15.5)
note. Values are expressed as no. (%) for qualitative variables and as
mean  standard deviation (SD) for quantitative variables. SAPS II, Sim-
plified Acute Physiology Score.
a The McNemar test was used to compare categorical variables, and the
paired Student t test was used to compare continuous variables.
PAFp CF # [(ROD 1)/ROD] ,E
where CFE is the case patient fraction exposed to ICU-ac-
quired NI and is the etiological fraction[(ROD 1)/ROD]
of attributable risk for case patients to be exposed at least
once to ICU-acquired NI.
To perform multivariate analysis and generate an adjusted
estimate of the PAF of death due to ICU-acquired NI, we
determined the PAF for multiple levels of exposure. An ex-
posure was defined as, for example, the presence in the ICU
of 1 patient with 1 pulmonary infection or 1 patient with 1
UTI. Then, to assess the sum of category-specific attributable
fractions, we used the following equation:25-27
PAFp 1 [CF (1/ROD )E1 1
 CF (1/ROD ) CF (1/ROD )] ,E2 2 E3 3
where CFE1, CFE2, and CFE3 are the exposure incidence in case
patients according to the different levels of exposure. The
quantities ROD1, ROD2, and ROD3 are the different RODs
according to the levels of exposure and type of ICU-acquired
NI (see above).
We computed the adjusted RODs and 95% confidence in-
tervals (CIs) with conditional multiple logistic regression
models.28,29 We incorporated different terms for the specific
ICU-acquired NI in the 5 models corresponding to different
polytomous “risk levels” of infection (see Appendix, Table
A). All covariates that reached a statistical threshold (P !
) in univariate analysis were included in a multivariable.10
model. All analyses were performed with SPSS for Windows,
version 10.1 (SPSS).
results
A total of 12,246 patients in 11 ICUs were registered in the
surveillance network during the study period. We excluded
all patients with incomplete data, leaving 8,068 potentially
eligible patients for analysis. The main reason for exclusion
was that data were missing for reliable assessment of the
presence or absence of ICU-acquired NI. The distribution of
missing data was as follows: 24 patients (0.2%) with missing
information on possible pulmonary infection, 4,137 patients
(33.8%) without information on CVC infection, 56 patients
(0.5%) without information on UTI, and 28 patients (0.2%)
without information on BSI. In total, data were missing for
4,178 patients (34.1%). Table 1 compares characteristics be-
tween included and excluded patients.
Among the 8,068 patients included in the study, the total
incidence of ICU-acquired NI was 20.8% during the study
period (annual range, 16.7% [in 2003] to 25.6% [in 1996];
). The range in total incidence among the differentP ! .001
ICUs was 6.3%–29.6% ( ). The mean annual inci-P ! .001
dence was 8.0% for pulmonary infection, 7.9% for CVC in-
fection, 7.6% for UTI, and 3.3% for BSI. During the study
period, 1,835 patients (22.7%) died before ICU discharge.
The crude mortality rate was 33.2% (556 of 1,677) for patients
who had contracted at least 1 ICU-acquired NI and 20.0%
(1,279 of 6,391) for patients without ICU-acquired NI during
their stay ( ).P ! .001
Overall, 1,725 case patients were successfully matched to
1,725 control patients (total ) for the final analysis.np 3,450
These 1,725 deceased patients represented 94% of all deceased
subjects from the source population of our study. Case pa-
tients and control patients differed by mean length of stay
( ), mean Simplified Acute Physiology Score IIPp .031
( ), immunocompromised status ( ), and typeP ! .001 P ! .001
of admission conditions ( ) (Table 2). During theP ! .001
study period, the incidence of ICU-acquired NI was 31.0%
for case patients and 19.5% for the control patients (P !
)..001
Attributable Mortality Due to ICU-Acquired NI
Table 3 presents crude and adjusted ROD in patients who
experienced at least 1 ICU-acquired NI. Each model provides
an estimate of the PAF for ICU mortality that relates to ICU-
acquired NI, stratified by type of infection and the number
of infected sites. The PAF for each of the 5 models of ICU-
acquired NI is reported in Table 4. The PAF due to ICU-
acquired NI in patients who died before ICU discharge was
14.6% (95% CI, 14.4%–14.8%), which means that of 100
deaths that occurred before ICU discharge, 14.6 were related
to an ICU-acquired NI. Stratified by type of infection, the
PAFs were 6.1% (95% CI, 5.7%–6.5%) for pulmonary in-
fection, 3.2% (95% CI, 2.8%–3.5%) for CVC infection, and
1.7% (95% CI, 0.9%–2.5%) for BSI. No significant propor-
tion of deaths was attributable to UTI when it was the pa-
tient’s only infected site (PAF, 0.0 [95% CI,0.4% to 0.4%]).
Under the assumption of the additive property of the statis-
tical model used, the sum of all infection-specific PAF values
was equal to the global PAF presented in model 1.25-27
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table 3. Relative Odds of Death (ROD) in Relation to Different Risk Levels of Intensive Care Unit (ICU)–Acquired
Nosocomial Infections (NIs) using Conditional Logistic Regression Models at 11 Intensive Care Units at the University
Hospital of Lyon, 1995–2003
Risk levels of ICU-acquired NI
Crude ROD Adjusted ROD
ROR (95% CI) P ROR (95% CI) P
Model 1
No infection 1.0 1.0
At least 1 pulmonary infection, CVC infection, UTI, or BSI 1.9 (1.6–2.2) !.001 1.9a (2.0–3.1) !.001
Model 2
No infection 1.0 1.0
Only 1 pulmonary infection 3.1 (2.2–4.20) !.001 3.3 (2.2–4.8) !.001
Pulmonary infection and at least 1 other infected site 3.3 (2.2–4.7) !.001 3.3 (2.1–5.1) !.001
At least 1 other infected site, pulmonary infection excluded 1.4 (1.1–1.6) .002 1.4 (1.1–1.7) !.001
Model 3
No infection 1.0 1.0
Only 1 CVC infection 1.8 (1.3–2.4) !.001 1.8 (1.3–2.5) !.001
CVC infection and at least 1 other infected site 2.4 (1.6–3.4) !.001 2.2 (1.4–3.4) !.001
At least 1 other infected site, CVC infection excluded 1.8 (1.5–2.2) !.001 1.9 (1.5–2.4) !.001
Model 4
No infection 1.0 1.0
Only 1 UTI 0.8 (0.6–1.1) .205 1.0 (0.6–1.3) .598
UTI and at least 1 other infected site 1.6 (1.1–2.3) .011 1.9 (1.2–2.9) !.001
At least 1 other infected site, UTI excluded 2.6 (2.1–3.1) !.001 2.5 (1.9–3.2) !.001
Model 5
No infection 1.0 1.0
Only 1 BSI 3.5 (1.9–6.8) !.001 3.9 (1.7–8.7) !.001
BSI and at least 1 other infected site 1.9 (1.3–2.9) .001 2.0 (1.2–3.3) !.001
At least 1 other infected site, BSI excluded 1.8 (1.5–2.1) !.001 1.8 (1.5–2.3) !.001
note. Adjusted on Simplified Acute Physiology Score II (SAPS) as categorical variable, immunocompromised status as dichot-
omous variable, and type of admission condition as categorical variable. BSI, bloodstream infection; CI, confidence interval; CVC,
central venous catheter; ROR, relative odds ratio; UTI, urinary tract infection.
a The ROD is increased by 1.9 in case patients who experienced at least 1 ICU-acquired NI, compared with case patients who did
not.
discussion
The objective of this study was to estimate the PAF for patient
deaths due to infection acquired before ICU discharge. The
3 major findings of this study were as follows: First, 14.6%
of deaths (95% CI, 14.4%–14.8%) might be attributed to
ICU-acquired NI. Second, to estimate mortality attributable
to ICU-acquired NI, it may be clinically useful and comple-
mentary to other, commonly risk-based, methods to use the
PAF concept. Third, exposure to ICU-acquired NI was an
important determinant of death in our population.
The proportion of deaths attributable to ICU-acquired NI
was likely associated with the incidence of exposure to in-
fections rather than with the ROD associated with the level
of infection. Therefore, the incidence of exposure to infections
was far more relevant than only the risk of infection by itself.
Because we analyzed attributable risk, in order to find the
effect of ICU-acquired NI on mortality, it was more appro-
priate to study the effect of incidence of infections than to
study the effect of risk of infection. For example, the ratio
of the ROD of 3.3 for pulmonary infection only (Table 4) to
the ROD of 1.4 for at least 1 infected site, pulmonary infection
excluded, was 2.4. In contrast, the number of deaths attrib-
utable only to PI was 6.1% (95% CI, 5.7%–6.5%) and the
number of deaths attributable to at least 1 infected site, PI
excluded, was 4.6% (95% CI, 4.3%–4.9%) (Table 4), so the
ratio of deaths attributable only to PI to deaths attributable
to at least 1 infected site, PI excluded, was only 1.3. This
lower ratio was due to computation of the death attributable
proportion, which was taken into account for the incidence
of exposure for case patients. The incidence of exposure to
only pulmonary infection was 8.7%, compared with 15.9%
for at least 1 infected site, pulmonary infection excluded. This
finding is an interesting contribution of this study,30-32 which
underscores the fact that a difference exists between the risk
for an event to occur (ie, excess risk) and the attributable
risk for the same event, depending on the incidence of ex-
posure to risk factors for that event. In theory, odds is the
ratio of the probability that an event of interest occurs to the
probability that it does not occur (in contrast, risk is the
probability for an event to occur within an exposed
population),33,34 while an attributable event refers to how
many events are the direct consequence of an exposure.34 This
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table 4. Population-Attributable Fraction (PAF) of Deaths According to Different Risk Levels
of Intensive Care Unit (ICU)–Acquired Nosocomial Infections (NIs) at 11 ICUs at the University
Hospital of Lyon, 1995–2003
Risk level of ICU-acquired NI CFE, % PAF, % (95% CI)
Model 1
At least 1 pulmonary infection, CVC infection, UTI, or BSI 31.0 14.6 (14.4–14.8)
Model 2
Only 1 pulmonary infection 8.7 6.1 (5.7–6.5)
Pulmonary infection and at least 1 other infected site 6.4 4.5 (4.0–5.0)
At least 1 other infected site, pulmonary infection excluded 15.9 4.6 (4.3–4.9)
Model 3
Only 1 CVC infection 7.2 3.2 (2.8–3.5)
CVC infection and at least 1 other infected site 5.3 2.9 (2.4–3.4)
At least 1 other infected site, CVC infection excluded 18.5 8.7 (8.4–9.1)
Model 4
Only 1 UTI 4.2 0.0 (0.4 to 0.4)
UTI and at least 1 other infected site 4.1 1.9 (1.4–2.4)
At least 1 other infected site, UTI excluded 22.7 13.6 (13.3–13.9)
Model 5
Only 1 BSI 2.3 1.7 (0.9–2.5)
BSI and at least 1 other infected site 3.8 1.9 (1.4–2.4)
At least 1 other infected site, BSI excluded 24.9 11.0 (10.8–11.2)
note. where CFE is the case patient fraction exposed to ICU-acquiredPAFp CF # [(ROD 1)/ROD],E
NI and is the etiological fraction of attributable risk for case patients to be exposed at[(ROD 1)/ROD]
least once to ICU-acquired NI. BSI, bloodstream infection; CVC, central venous catheter; UTI, urinary tract
infection.
concept has not been adequately explored in the field of hos-
pital-acquired infections, compared with other public health
domains.35-37
For clinical practice, these findings could be of major in-
terest. Table 4 reports that 14.6% (95% CI, 14.4%–14.8%)
of deaths during ICU stay are attributable to ICU-acquired
NI, whatever the site of infection. For pulmonary infection
only or pulmonary infection with a coinfection, the propor-
tion of deaths attributable to pulmonary infection was 10.6%.
For CVC infection only or CVC infection with a coinfec-
tion, the proportion of deaths attributable to CVC infection
was 6.1%. Interventions to reduce the mortality attributable
to ICU-acquired NI should be focused on these 2 sites of
infection because of their high incidence. In particular, be-
cause of their incidence and potential effect on mortality,
pulmonary infections should be a primary target for inter-
ventions. A recent study has demonstrated that prevention
of ventilator-associated pneumonia by means of selective di-
gestive tract decontamination and selective oropharyngeal de-
contamination can reduce ICU and 28-day mortality, com-
pared with no intervention.38 Additional and less controversial
preventive measures to decrease exogenous or endogenous
cross-transmission to prevent ventilator-associated pneumonia
should be considered. For instance, increased compliance with
hand hygiene, short duration of intubation, nonprofound se-
dation, and correct patient positioning may help to decrease
rates of ventilator-associated pneumonia rates and ultimately
to decrease the likelihood of death.
For decades, the method chosen for this study has been
used in chronic disease epidemiology to examine attributable
mortality. Conceptually, we assumed that the ROD was dif-
ferent from the total number of deaths related to an exposure,
allowing estimation of the “etiological fraction,” as proposed
by Samore and Harbarth.39 The advantage of our method of
calculating the PAF is that it takes into account multiple levels
of exposure (pulmonary infection, CVC infection, UTI, and
BSI). This stems from the PAF concept developed by Levin
in 1953:40 when risk is multilevel (at least 2 categories), con-
founders are present, and risk adjustment is needed.26,27
Some limitations must be addressed. For each patient, only
the first infection by site was considered for analysis. More-
over, the cumulative effect of repeated infections was not
estimated. The analysis was not stratified by the causative
microorganisms responsible for the infection. It was not pos-
sible to match or adjust for the causative organisms because
infections were frequently polymicrobial. However, a similar
study design could be used for patients infected by a specific
microorganism of high clinical interest (eg, Staphylococcus
aureus or Pseudomonas aeruginosa). In future studies, analysis
stratified by microorganism might be helpful to identify the
pathogens that are associated with the worst prognosis.41-43
Since our estimate of ROD is closer to an odds ratio than to
a relative risk, the strength of association could have been
overestimated. In addition, the lower incidence of death in
the population that was excluded from the analysis because
of missing data on ICU-acquired NI ( ) could haveNp 4,178
biased our results. In consequence, the true proportion of
attributable deaths due to ICU-acquired NI might be lower
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than in our results. Finally, residual confounding factors can-
not be excluded, owing to the design of the surveillance net-
work, since data were collected prospectively for surveillance
of ICU-acquired NI and not primarily for survival analysis.
conclusions
In summary, the results of this study strongly suggest that an
important proportion of ICU deaths was caused by NI. These
results support previous evidence that death and ICU-ac-
quired NI are causally linked, but the strength of the asso-
ciation may vary according to the methodological approach
taken. The method reported in this study could be considered
complex because it has not often been used in the field;
however, the use of this method can yield additional results
to illuminate a controversial issue. The incidence of exposure
was a major determinant identified by use of our method.
Therefore, one way to estimate the contribution of ICU-ac-
quired NI to mortality might be based on estimation of the
PAF, which takes into account the incidence of exposure to
ICU-acquired NI.
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appendix
table a. Five Models, Stratified by Type of Nosocomial Infections (NIs) Acquired in the Intensive Care
Unit (ICU) and Risk Levels
Risk level Definition
Model 1: ICU-acquired pulmonary infection,
CVC infection, UTI, and/or BSI
0 No infection
1 At least 1 pulmonary infection, CVC infection, UTI, or BSI
Model 2: ICU-acquired pulmonary infection
0 No infection
1 Only 1 pulmonary infection
2 Pulmonary infection and at least 1 other infected site
3 At least 1 other infected site, pulmonary infection excluded
Model 3: ICU-acquired CVC infection
0 No infection
1 Only 1 CVC infection
2 CVC infection and at least 1 other infected site
3 At least 1 other infected site, CVC infection excluded
Model 4: ICU-acquired UTI
0 No infection
1 Only 1 UTI
2 UTI and at least 1 other infected site
3 At least 1 other infected site, UTI excluded
Model 5: ICU-acquired BSI
0 No infection
1 Only 1 BSI
2 BSI and at least 1 other infected site
3 At least 1 other infected site, BSI excluded
note. BSI, bloodstream infection; CVC, central venous catheter; UTI, urinary tract infection.
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